Verve is developing drug candidates for heart disease, including the PCSK9-targeted VERVE-102, a base-editing therapy.

The project will leverage Noetik's AI model and multimodal spatial data to search for biomarkers of patient response to Agenus' immunotherapy regimen.

The firm will assess irpagratinib plus best supportive care in patients with FGF19-overexpressing advanced liver cancer.

The firm is developing the PHOX2B-targeted cell therapy, which has shown promise in preclinical xenograft models, with CHOP researchers.

The firm will stop shipping the gene therapy for these patients until a new immunosuppressive regimen is approved for managing acute liver failure.

The agency approved a perioperative Keytruda regimen based on a 30 percent reduction in the risk of recurrence, progression, or death versus the control arm.

Studies doing genome-wide testing can easily ID patients with naturally low neutrophil counts, but nobody's looking at it, ...

Medical ethicists are bringing attention to an early chapter of precision medicine history, an often overlooked aspect of an ...

Trump administration health officials assured drugmakers and researchers at a roundtable hosted by the FDA that they want to ...

Only 6 percent of patients carried a concerning DPYD variant, but nearly two-thirds of them were later hospitalized after ...

As with the drug's 2023 approval in castration-resistant tumors, it's not clear if it works comparably in all homologous ...

The drug is already approved for KMT2A-rearranged AML, and Syndax is hoping for approval in NPM1-mutated disease by the end of the year.